We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Trellus Health Plc | TRLS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.15 | 8.57% | 1.90 | 11:00:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.75 | 1.75 | 1.90 | 1.90 | 1.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 24/4/2024 18:09 by davr0s Crikey I inherited some of these as a dividend payment from EKF some years ago. My holding is currently valued at £1.90 lol. What am I supposed to do with this?? |
Posted at 01/12/2023 12:24 by hatfullofsky TRLS are now trading 40% below their cash level |
Posted at 01/9/2023 13:06 by hatfullofsky Breakeven is on the IMC slide deckAt $100 per patient per month, breakeven at 6200 members (2.5% of TAM)Cash at $19m 2022 v $24m 2021, burn below $700k per month in 2023, cash into 2025 (at current revenue levels and capital investment)In early and late stage discussions with several health plans 2023 expecting revenue take off as 2022 pilot contracts roll into commercial agreements.130 patients currently enrolled (a long way to 6200)TRLS need to announce contracts and enrolment numbers for this to recover |
Posted at 11/4/2023 09:31 by mikemine1 TRLS seems to fit right in there with the Commission's view of the future. Well done Wan. |
Posted at 13/2/2023 07:55 by wan With today's news, that now completes 3 of contracts highlighted in Trellus' Half-year Report -Significant progress with advancing B2B2C model I am very pleased to report that, despite the longer lead times in the B2B2C contracting process as previously reported in December 2021, we have made significant progress in advancing a number of conversations with payers , such as regional and national health plans, employers, health systems, GI provider networks, and pharmaceutical companies. Whilst we have launched our D2C model, we remain focused on our B2B2C offering which provides better quality patient outcomes at lower costs to health plans and employers. We are in productive conversations with two health plans, having entered late-stage discussions with one and starting the due diligence process with another; we are in the final contracting phase for a New York Medicaid plan and we have two further contracts, one with a large NY State employer and the other with a NY State Provider to support members of a large NY labor union, which we expect to be signed soon. We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform. Expansion into Irritable Bowel Syndrome (IBS) for comprehensive GI solution Hopefully we will see continued execution in IBS expansion and the pharma discussions/contract |
Posted at 06/12/2022 09:43 by wan Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only.I note that Trellus has updated/revamped their website - Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. A reminder - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." |
Posted at 11/11/2022 07:29 by wan Medtech execs ‘rethink&rsquoPublished Nov. 10, 2022 Dive Brief: More than 75% of surveyed medtech executives expect expanding care settings and delivery models to “significantly re-orient their company’s long-term strategy.” Dive Insight: The COVID-19 pandemic accelerated shifts that were already underway in the industry, notably moves from in-person to virtual interactions and from hospital to ambulatory care centers. According to Accenture’s report, which is based on the survey and interviews with 30 digital health senior executives and C-suite leaders, the shift in where care happens is only just beginning. “We estimate that 80% to 90% of chronic and behavioral care can shift to virtual. It means that providers are able to work to the full extent of their medical training, rather than burning time on more menial tasks,” an unidentified executive at AdvaMed’s Digital Health Center of Excellence said in the report. The surveyed and interviewed executives expect to transform their businesses in response to the shifts in how care is delivered. While traditional products still account for most sales, the executives see the expansion of care to new settings as part of their growth strategies. Accenture cited the use of diagnostic tests at physician’s offices or at home, rather than at large hospital labs, as an example of the changes. Full article - The above sits well with the recent news from Trellus - LONDON, U.K. AND NEW YORK, U.S. (19 October 2022): Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that the Trellus Resilience Training and Self-Management Solution for Inflammatory Bowel Disease (the "Trellus IBD program") is now available on GI OnDemand, gastroenterology's leading multidisciplinary virtual integrated care platform . GI OnDEMAND, a joint venture between the American College of Gastroenterology ("ACG") and Gastro Girl, Inc., now offers the Trellus IBD program, to all GI OnDEMAND and ACG members nationwide to coordinate and deliver personalized behavioral, emotional and nutritional support for their IBD patients remotely via digital solutions, and access to an expert resilience team via telehealth . The Trellus IBD program will be the only resilience driven self-management training solution offered via this platform to over 16,000 gastrointestinal ("GI") professionals across the US for the benefit of the millions of patients they collectively serve. |
Posted at 10/11/2022 19:53 by mikemine1 One very attractive aspect of the business model, as far as I can see, is that, once a patient comes on to the programme, they stay for a very long time, possibly for life. This means that TRLS have only one sale to make, if you like, to acquire a very long term pipeline of revenue. It's cumulative and should not be a linear growth as more and more clinicians should join the band of referrers.This could be very big but patience will be required. All my own opinion of course. |
Posted at 21/10/2022 04:17 by mikemine1 Think of markets, link-ups, contracts etc. all you like but, for me, the big number here is TRLS has said they only need 8,000 patients to break even. Now look at all the potential patients the fore mentioned access points open up to Trellus. Do you think that number will come out of those tie-ups? To me it's a no brainer that the 8.000 will be exceeded and that means profit. The only question for me is when?Ramp over................ |
Posted at 23/12/2021 10:32 by adobbing Question around In Specie shares from EKF.Below is from the Corporate action on EKF dated 24/12/20. When do these become available, is it tomorrow or longer? Terms: 1 A share in Trellus Health Limited for every 16.25 EKF Diagnostics Holdings plc shares held Ex-entitlement date: 16th December 2020 EKF Diagnostics Holdings plc has announced a distribution in specie, whereby holders will be issued with 1 A ordinary share in Trellus Health Limited for every 16.25 existing shares in EKF Diagnostics Holdings plc held. The ex-entitlement date is 16th December 2020. EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited, at which time an `omnibus` share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled. During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. The A Shares will, on the earlier of the admission to trading of Trellus on AIM (or another recognised stock exchange) and two years from the date that the Dividend is settled, automatically convert into ordinary shares in Trellus on the basis of one Ordinary Share for each A Share held. If Trellus is admitted to trading on AIM (or another recognised stock exchange), the Lock-up Period will continue to apply to the converted Ordinary Shares. All converted Ordinary Shares will rank equally in all respects with all other Ordinary Shares including in respect of voting and dividend rights. The legal title to the Dividend Shares will be held by Broadway as trustee, during the Lock-Up Period. If the A Shares are converted into Ordinary Shares during the Lock-up Period, Broadway will request that Trellus` registrar seeks the voting instructions of the Relevant EKF Shareholders in relation to any shareholder resolution of Trellus and will vote those Dividend Shares in accordance with such instructions as it receives. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
